Patents Assigned to ALECTOR LLC
-
Patent number: 11208488Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: September 18, 2018Date of Patent: December 28, 2021Assignee: Alector LLCInventors: Arnon Rosenthal, Tina Schwabe, Michael Kurnellas, Robert Pejchal, Anthony B. Cooper
-
Publication number: 20210395361Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a Siglec-5 protein, e.g., human Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: July 26, 2019Publication date: December 23, 2021Applicant: Alector LLCInventors: Patricia CULP, Rashmi BANKOTI, Helen LAM, Arnon ROSENTHAL
-
Patent number: 11186645Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: January 13, 2020Date of Patent: November 30, 2021Assignee: Alector LLCInventors: Arnon Rosenthal, Tina Schwabe, Michael Kurnellas, Robert Pejchal, Anthony B. Cooper
-
Patent number: 11174313Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: June 11, 2016Date of Patent: November 16, 2021Assignee: ALECTOR LLCInventors: Arnon Rosenthal, Kate Monroe, Francesca Avogadri-Connors
-
Patent number: 11147249Abstract: Provided herein are transgenic non-human animals whose genomes comprise two or more human genes selected from CD33, Siglec-5, Siglec-7, Siglec-9, Siglec-11, Siglec-14, and Siglec-16, to methods of screening candidate agents that bind to and/or modulate the function and/or activity of at least one of the human genes in the transgenic non-human animals, and to methods of screening candidate agents to determine their effect on one or more activities and/or functions associated with expression of at least one of the human genes in the transgenic non-human animals. Further provided herein are methods of recapitulating a human Siglec immune system in a non-human animal, and methods of generating a non-human animal disease model comprising a human Siglec repertoire.Type: GrantFiled: December 8, 2017Date of Patent: October 19, 2021Assignee: ALECTOR LLCInventors: Arnon Rosenthal, Seung-Joo Lee
-
Publication number: 20210317208Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a CD33 polypeptide, e.g., a mammalian CD33 or human CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: August 30, 2019Publication date: October 14, 2021Applicant: Alector LLCInventors: Patricia CULP, Helen LAM, Wei-Hsien HO, Leonard G. PRESTA, Arnon ROSENTHAL
-
Patent number: 11136390Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: June 11, 2016Date of Patent: October 5, 2021Assignee: ALECTOR LLCInventors: Kate Monroe, Helen Lam, Francesca Avogadri-Connors, Seung-Joo Lee, William Monteith, Herve Rhinn, Arnon Rosenthal
-
Publication number: 20210284710Abstract: The present disclosure is generally directed to Siglec-9 ECDs and Siglec-9 ECD fusion molecules, and methods of treatment using Siglec-9 ECDs and Siglec-9 ECD fusion molecules.Type: ApplicationFiled: November 3, 2020Publication date: September 16, 2021Applicant: Alector LLCInventors: Spencer Liang, Samuel Nalle, Jeonghoon Sun, Hua Long, Rashmi Bankoti
-
Publication number: 20210277113Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRP?1 polypeptide, e.g., a human SIRP?1, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: June 28, 2019Publication date: September 9, 2021Applicant: Alector LLCInventors: Andrew Pincetic, Patricia Culp, Arnon Rosenthal
-
Publication number: 20210246204Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: June 7, 2019Publication date: August 12, 2021Applicant: Alector LLCInventors: Patricia CULP, Seung-Joo LEE, Helen LAM, Wei-Hsien HO, Arnon ROSENTHAL
-
Patent number: 11084875Abstract: The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.Type: GrantFiled: April 11, 2019Date of Patent: August 10, 2021Assignee: ALECTOR LLCInventors: Kate Monroe, Tina Schwabe, Francesca Avogadri-Connors, Ilaria Tassi, Helen Lam, Arnon Rosenthal
-
Publication number: 20210139581Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: May 7, 2020Publication date: May 13, 2021Applicant: ALECTOR LLCInventors: Patricia CULP, Helen LAM, Arnon ROSENTHAL, Seung-Joo LEE, Nels P. NIELSON, Robert PEJCHAL
-
Publication number: 20210121583Abstract: The present disclosure provides methods of screening for a sortilin binding antagonist. In some embodiments, the methods include incubating an agent with a sortilin protein and a sortilin ligand, where the sortilin protein and sortilin ligand are each attached to a member of a fluorescence donor/acceptor pair, exciting the fluorescence donor of the fluorescence donor/acceptor pair, and detecting fluorescence emitted by the fluorescence donor at a second wavelength and fluorescence emitted by the fluorescence acceptor at a third wavelength. A decrease in the ratio of the fluorescence emitted by the fluorescence acceptor at the third wavelength to the fluorescence emitted by the fluorescence donor at the second wavelength, as compared to the ratio in the absence of the agent, indicates that the agent is a sortilin binding antagonist.Type: ApplicationFiled: November 3, 2020Publication date: April 29, 2021Applicant: Alector LLCInventors: Arnon ROSENTHAL, Tina SCHWABE
-
Publication number: 20210101978Abstract: The present disclosure is related to compositions that include polynucleotides encoding chimeric receptors, methods of delivering polynucleotides encoding chimeric receptors to immune cells, and methods of using immune cells encoding chimeric receptors to treat or prevent cancer.Type: ApplicationFiled: November 30, 2020Publication date: April 8, 2021Applicant: Alector LLCInventor: Arnon ROSENTHAL
-
Publication number: 20210095023Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-9 protein, e.g., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: September 10, 2020Publication date: April 1, 2021Applicant: Alector LLCInventors: Arnon Rosenthal, Kate Monroe, Seung-Joo Lee
-
Publication number: 20210017275Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-5 protein, e.g., human Siglec-5 or a mammalian Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: May 15, 2018Publication date: January 21, 2021Applicant: Alector LLCInventors: Kate MONROE, Helen LAM, Patricia CULP, Arnon ROSENTHAL
-
Patent number: 10875919Abstract: The present disclosure is related to compositions that include polynucleotides encoding chimeric receptors, methods of delivering polynucleotides encoding chimeric receptors to immune cells, and methods of using immune cells encoding chimeric receptors to treat or prevent cancer.Type: GrantFiled: April 26, 2017Date of Patent: December 29, 2020Assignee: ALECTOR LLCInventor: Arnon Rosenthal
-
Publication number: 20200392229Abstract: The present disclosure is generally directed to the use of compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, in treating and/or delaying progression of a disease or injury in an individual in need thereof.Type: ApplicationFiled: June 10, 2020Publication date: December 17, 2020Applicant: Alector LLCInventors: Robert PAUL, Michael F. WARD, Hua LONG, Shiao-Ping LU, Omer Rizwan SIDDIQUI, Arnon ROSENTHAL, Herve RHINN
-
Patent number: 10849992Abstract: The present disclosure provides methods of screening for a sortilin binding antagonist. In some embodiments, the methods include incubating an agent with a sortilin protein and a sortilin ligand, where the sortilin protein and sortilin ligand are each attached to a member of a fluorescence donor/acceptor pair, exciting the fluorescence donor of the fluorescence donor/acceptor pair, and detecting fluorescence emitted by the fluorescence donor at a second wavelength and fluorescence emitted by the fluorescence acceptor at a third wavelength. A decrease in the ratio of the fluorescence emitted by the fluorescence acceptor at the third wavelength to the fluorescence emitted by the fluorescence donor at the second wavelength, as compared to the ratio in the absence of the agent, indicates that the agent is a sortilin binding antagonist.Type: GrantFiled: April 7, 2016Date of Patent: December 1, 2020Assignee: ALECTOR LLCInventors: Arnon Rosenthal, Tina Schwabe
-
Patent number: 10800844Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-9 protein, e.g., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: October 28, 2016Date of Patent: October 13, 2020Assignee: ALECTOR LLCInventors: Arnon Rosenthal, Kate Monroe, Seung-Joo Lee